Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Palermo – page 19

380 clinical trials in Palermo, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Palermo at a glance
380
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

380 trials in Palermo

Open in trial search

Chronic obstructive pulmonary disease

Not recruiting

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Sjogren's syndrome

Not recruiting

Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Vib1116
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Lung adenocarcinoma

Not recruiting

Durvalumab versus standard chemotherapy drug combination in elderly patients with advanced non‑small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Carboplatin
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Plasma cell myeloma refractory

Not recruiting

A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
  • Sponsor:Janssen Cilag International

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Colitis ulcerative

Not recruiting

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.

Relapsing multiple sclerosis

Not recruiting

Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative+1

Not recruiting

A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Congenital absence of bile ducts

Not recruiting

Efficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Thalassaemia beta

Not recruiting

Evaluation of the Efficacy, Safety, and Tolerability of Subcutaneous REGN7999 in Adults with Iron Overload Due to Non-Transfusion Dependent Beta-Thalassemia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:REGN7999
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 233 cities in Italy

Clinical research in Palermo

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic colorectal cancer treatments and novel approaches for multiple myeloma. Studies are evaluating targeted therapies for diffuse large B-cell lymphoma and investigating new treatment combinations for various cancer types.

  • Colorectal Cancer Treatment Strategies
  • Lymphoma Therapy Development
  • Multiple Myeloma Management

Advanced research includes evaluation of targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into heart failure prevention and cardiovascular disease management. Clinical trials are examining new therapeutic approaches for pulmonary arterial hypertension and innovative treatments for cardiovascular complications.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Hypertension Treatment

Focus on developing preventive strategies and novel therapeutic interventions.

03 Autoimmune Disorders

Groundbreaking research investigating treatments for multiple sclerosis and systemic sclerosis. Studies evaluate new biological therapies and innovative approaches for managing autoimmune conditions including psoriatic arthritis.

  • Multiple Sclerosis Therapies
  • Inflammatory Disease Management
  • Autoimmune Treatment Innovation

Emphasis on developing targeted therapies for various autoimmune conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.